Early Life Exposures and Subsequent Cancer Risk

生命早期的暴露和随后的癌症风险

• 批准号: 7288902
• 负责人: Robert Hoover
• 金额: --
• 依托单位: DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7288902
• 关键词: Early; Life; Exposures; Subsequent; Cancer

00020 - Diethylstilbestrol (DES), a drug first synthesized in 1938, was administered to several million pregnant women in the U.S. and Europe for the prevention of spontaneous abortion and premature delivery. In 1971, Herbst reported a strong association between DES use in pregnancy and the occurrence of vaginal clear cell adenocarcinoma (CCA) in exposed female offspring. Animal models have demonstrated a range of DES effects on offspring exposed in utero, including reproductive dysfunction, immune system changes, behavioral and sexual abnormalities, and increases in various reproductive cancer in males and females. NCI, in collaboration with five field centers, reassembled previously studied cohorts of DES-exposed and unexposed mothers, daughters and sons, and identified subjects with documented exposure status who had not been studied previously, through familial links within the cohorts. Standardized baseline questionnaires were mailed to cohort members to ascertain the risk of cancer and other disorders. Pathology reports were collected for reported cancers and preneoplastic conditions. Theree separate phases of follow-up have been conducted. The purpose of this study is to continue the follow-up, by means of mailed questionnaires and medical record collection, which was begun during the the first phase of the study. Concern has arisen that DES-exposed daughters may be at higher risk of breast cancer. Exposure to high levels of endogenous estrogen in utero has been hypothesized to increase the risk of breast cancer and DESis a potent estrogen. Cacner risk in the sons will also continure to be assessed, especailly for increased risks of prostate cancer. since the offspring who were exposed to DES in utero are currently reaching their late forties, when cancer rates begin to rise, it is important to continue the follow-up of these cohorts to determine if there are long-term increases in cancer risk. 10039 - The proposed study involves collecting maternal and cord blood samples from monochorionic twin, dichorionic twin and singleton pregnancies of similar gestational age to quantify differences in concentrations of several hormones and other pregnancy products including estriol, estradiol, estrone, testosterone, androstenedione, dehydroepiandrosterone (DHEA), DHEA-sulfate, progesterone, AFP, prolactin, IGF and IGF-binding protein 3. Data from medical records and pathology reports will be abstracted to provide information on the mother, baby, pregnancy and placenta. The work will be done at Dartmouth Hitchcock Medical Center, Dartmouth Medical School. Blood samples labeled with a unique ID number only will be sent to Bioreliance, NCI's contractor, for preperation and shipment to the laboratory that will perform the hormone assays. NCI will receive the abstracted data in electronic form. no personal identifying information will be received by NCI or its contractor. The study has been approved by Dartmouth Medical School. 10041 - The Norwegian birth and cancer registries will be used to investigate the association of several pregnancy and perinatal factors and risk of cancer in adult offspring. 10032 - Collaboration with NICHD on a study of preeclampsia conducted at Louisiana State University Health Sciences Center. Blood samples are being collected from mothers and from umbilical cords with and without preeclampsia. The relationship of pregnancy hormone levels and preeclampsia will be analyzed. 01132 - In this study using data from a cohort study of preeclamptic and uncomplicated pregnancies at the University of Pittsburgh, we are analyzing maternal and cord blood samples from preeclamptic and normal pregnancies of similar gestational age to quantify differences in levels of various hormones. We will evaluate associations of several maternal, perinatal and pregnancy factors, such as maternal age and birth weight, with hormone levels in normal pregnancies.

00020 - 己烯雌酚 (DES) 是一种于 1938 年首次合成的药物，在美国和欧洲为数百万孕妇服用，用于预防自然流产和早产。 1971 年，Herbst 报告称，怀孕期间使用 DES 与暴露的雌性后代发生阴道透明细胞腺癌 (CCA) 之间存在密切关联。动物模型已证明 DES 对子宫内暴露的后代产生一系列影响，包括生殖功能障碍、免疫系统变化、行为和性异常，以及男性和女性各种生殖癌症的增加。 NCI 与五个现场中心合作，重新组合了先前研究的 DES 暴露和未暴露母亲、女儿和儿子的队列，并通过队列中的家庭联系识别出之前未曾研究过的记录有暴露状态的受试者。标准化基线调查问卷被邮寄给队列成员，以确定癌症和其他疾病的风险。收集所报告的癌症和癌前病症的病理学报告。已经进行了三个单独阶段的后续行动。本研究的目的是通过邮寄问卷和收集病历的方式继续进行在研究第一阶段开始的随访。人们担心接触 DES 的女儿患乳腺癌的风险可能更高。据推测，在子宫内接触高水平的内源性雌激素会增加患乳腺癌的风险，而 DES 是一种有效的雌激素。儿子们的癌症风险也将继续进行评估，特别是前列腺癌风险的增加。由于在子宫内接触 DES 的后代目前已年届四十多岁，此时癌症发病率开始上升，因此继续对这些队列进行随访以确定癌症风险是否长期增加非常重要。 10039 - 拟议的研究涉及从胎龄相似的单绒毛膜双胞胎、双绒毛膜双胞胎和单胎妊娠中收集母体和脐带血样本，以量化几种激素和其他妊娠产物的浓度差异，包括雌三醇、雌二醇、雌酮、睾酮、雄烯二酮、脱氢表雄酮（ DHEA)、DHEA-硫酸盐、黄体酮、AFP、催乳素、 IGF 和 IGF 结合蛋白 3. 将提取医疗记录和病理报告中的数据，以提供有关母亲、婴儿、妊娠和胎盘的信息。这项工作将在达特茅斯医学院的达特茅斯希区柯克医疗中心完成。仅标有唯一 ID 号的血液样本将被发送至 NCI 的承包商 Bioreliance 进行准备并运送至进行激素检测的实验室。 NCI 将收到电子形式的摘要数据。 NCI 或其承包商不会收到任何个人识别信息。该研究已得到达特茅斯医学院的批准。 10041 - 挪威出生和癌症登记处将用于调查多种妊娠和围产期因素与成年后代患癌症风险之间的关系。 10032 - 与 NICHD 合作在路易斯安那州立大学健康科学中心进行了一项先兆子痫研究。从患有或不患有先兆子痫的母亲和脐带中采集血液样本。将分析妊娠激素水平与先兆子痫的关系。 01132 - 在这项研究中，我们使用匹兹堡大学的先兆子痫和无并发症妊娠队列研究的数据，分析了孕龄相似的先兆子痫和正常妊娠的母体和脐带血样本，以量化各种激素水平的差异。我们将评估一些产妇、围产期和妊娠因素（例如产妇年龄和出生体重）与正常妊娠中激素水平的关联。